Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

International Clinical Psychopharmacology

Volumn 14, Issue 1, 1999, Pages 19-28

  Feiger, Alan D ^a,g   Bielski, Robert J ^b   Bremner, James ^c   Heiser, Jon F ^d   Trivedi, Madhukar ^e   Wilcox, Charles S ^d   Roberts, Douglas L ^f   Kensler, Terry T ^f   McQuade, Robert D ^f   Kaplita, Stephen B ^f   Archibald, Donald G ^f  

^a Feiger PsychMed Center   (United States)

^b Institute for Health Studies   (United States)

^c Bremner Research Institute   (United States)

^d Pharmacology Research Institute   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g Feiger Health Research Center   (United States)

Author keywords

Continuation treatment; Major depression; Nefazodone; Placebo; Relapse prevention

Indexed keywords

NEFAZODONE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SINGLE BLIND PROCEDURE;

EID: 0032929381     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199901000-00002     Document Type: Article

References (58)

1. Anton SF, Robinson DS, Roberts DL, Kensler TT, English PA, Archibald DG (1994) Long-term treatment of depression with nefazodone. Psychopharmacol Bull 30:165-169.
2. Armitage R, Yonkers K, Cole D, Rush AJ (1997) A multicenter, double-blind comparison of the effects of nefazodone and fluoxetine on sleep architecture and quality of sleep in depressed outpatients. J Clin Pyschopharmacol 17:161-168.
3. Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, et al. (1996) A multicenter double-blind comparison of nefazodone and paroxetine in the treatment or outpatients with moderate-to-severe depression. J Clin Pyschopharmacol 57 (Suppl. 2):53-62.
4. Baldwin DS, Thomas SC, Birtwistle J (1997) Effects of antidepressant drugs on sexual function. Int J Psychiatry Clin Pract 1:47-58.
5. Barr LC, Goodman WK, Price LH (1994) Physical symptoms associated with paroxetine discontinuation. Am J Psychiatry 151:289.
6. Blazer D (1989) Depression in the elderly. N Engl J Med 320:164-166.
7. Brown WA, Khan A (1994) Which depressed patients should receive antidepressants? CNS Drugs 1:341-347.
8. Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR (1996) Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 57 (Suppl. 2):15-18.
9. Consensus Development Panel (1985) Mood disorders: pharmacologic prevention of recurrences. Am J Psychiatry 142:469-476.
10. Coppen A, Mendlewicz J, Kielholz P (1986) Pharmacotherapy of Depressive Disorders: A Consensus Statement. Geneva: World Health Organization.
11. Coupland NJ, Bell CJ, Potokar JP (1996) Serotonin reuplake inhibitor withdrawal. J Clin Psychopharmacol 16:356-362.
12. Dilsaver SC (1994) Withdrawal phenomena associated with antidepressant and antipsycholic agents. Drug Safety 10:103-114.
13. Dilsaver SC, Greden JF (1984) Antidepressant withdrawal phenomena. Biol Psychiatry 19:237-256.
14. Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Br J Psychiatry 160:217-222.
15. Einbinder MD (1995) Fluoxetine withdrawal? Am J Psychiatry 152:1235.
16. Fava GA, Grandi S (1995) Withdrawal syndromes after paroxctine and sertraline discontinuation. J Clin Psychopharmacol 15:374-375.
17. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF (1997) Emergence of adverse events following discontinuation of treatment with extended-release. Am J Psychiatry 154:1760-1762.
18. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS (1996) Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 57 (Suppl. 2), 53-62.
19. Feighner J, Targum SD, Bennett ME, Roberts DL, Kensler TT, D'Amico MF, Hardy SA (1998) A double-blind, placebo-controlled trial of nefazodone in the treatment of patients hospitalized for major depression. J Clin Psychiatry 59:246-253.
20. Ferguson JM, Shrivastava RK, Stahl SM, Hartford JJ, Nape B, Borian F (1996) Effects of double-blind treatment with nefzaodone or sertraline on re-emergence of sexual dysfunction in depressed patients. In: American Psychiatric Association Abstracts. p. 164.
21. Fontaine R, Ontiveros A, Elie R, Kensler TT, Roberts DL, Kaplita S, et al. (1994) A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 55:234-241.
22. Frank E, Kupfer DJ, Hamer T, Grochocinski VJ, McEachran AB (1992) Maintenance treatment and psychobiologic correlates of endogenous subtypes. J Affect Dis 25:181-190.
23. Frank E, Kupfer DJ, Perel JM, Cornes C, Jarrett DB, Mallinger AG, et al. (1990) Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093-1099.
24. Frost L, Lal S (1995) Shock-like sensations after discontinuation of selective serotonin reuptake inhibitors. Am J Psychiatry 152:810.
25. Garner EM, Kelly MW, Thompson DF (1993) Tricyclic antidepressant withdrawal syndrome. Ann Pharmacother 27:1068-1072.
26. Georgotas A, McCue RE, Cooper TB (1989) A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 46:783-786.
27. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ (1997) A comparison of nefazodone and fluoxetine on mood and on objective, subjective and clinician-rated measures of sleep in depressed patients: a double-blind, 8-week clinical trial. J Clin Psychiatry 58:185-192.
28. Gold PW, Goodwin FK, Chrousos GP (1988) Clinical and biochemical manifestations of depression. N Engl J Med 319 413-420.
29. Kalbfleisch JD, Prentice RL. (1980) The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc.
30. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
31. Klerman GL (1978) Long term treatment of affective disorders. In: Psychopharmacology: A Generation of Progress (MA Lipton, A DiMascio, KF Killam, eds), New York, NY: Raven Press. pp. 1303-1311.
32. Klerman GL, Weissman MM, Frank E, Kocsis JH, Markowitz JC, Montgomery S (1994) Evaluating drug treatments of depressive disorders. In: Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines (RF Prien, DS Robinson, eds), New York, NY: Raven Press, pp. 281-325.
33. Koopowitz LF, Berk M (1995) Paroxetine induced withdrawal effects. Hum Psychopharmacol 10:147-148.
34. Loonen AJM, Peer PGM, Zwanikken GJ (1991) Continuation and maintenance therapy with antidepressive agents. Meta-analysis of research. Pharm Weekbl Sci 13:167-175.
35. Louie AK, Lannon RA, Ajari LJ (1994) Withdrawal reaction after sertraline discontinuation. Am J Psychiatry 151:450-451.
36. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L (1992) Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 149:795-800.
37. Mendels J, Reimherr F, Marcus RN, Roberts DL, Francis RJ, Anton SF (1995) A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients. J Clin Psychiatry 56 (Suppl. 6):30-16.
38. Mindham RHS, Howland C, Shepherd M (1973) An evaluation of continuation therapy with tricyclic antidepressants in depressive illness. Psychol Med 3:5-17.
39. Montgomery SA ( 1996) Efficacy of nefazodone in the treatment of depression. J Psychopharmacol 10 (Suppl. 1):5-10.
40. Montgomery SA, Dunbar G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8:189-195.
41. Montgomery SA, Doogan DP, Burnside R (1991) The influence of different relapse criteria on the assessment of long-term efficacy of sertraline. Int Clin Psychopharmacol 6 (Suppl 2):37-46.
42. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferrey G, et al. (1988) The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 153 (Suppl. 3):69-76.
43. Montgomery SA, Rasmussen JGC, Tanghøj P (1993) A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8:181-188.
44. Montgomery SA, Roberts A, Patel AG (1994) Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacol 9 (Suppl 1):49-53.
45. Jacoby R for Old Age Depression Interest Group (1993) How long should the elderly take antidepressants? A double-blind placebo-controlled study of continuation/ prophylaxis therapy with dothiepin. Br J Psychiatry 162:175-182.
46. Price JS, Waller PC, Wood SM, Mackay AVP (1996) A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacology 42:757-763.
47. Rickeis K, Schweizer E, Gary C, Fox J, Weise C (1994) Nefazodone and imipramine in major depression: a placebo-controlled trial. Dr J Psychiatry 164:802-805.
48. Rioux P, Kibleur Y, Franchon O, von Frenckell R, Zariffian F (1996) A double-blind comparison of nefazodone and fluoxetine in depressed outpatients. In: American Psychiatric Association Abstracts. p. 164.
49. Robinson DS, Lerfald SC, Bennett B, Laux C, Devereaux E, Kayser A, et al. (1991) Continuation and maintenance treatment of major depression with the monoamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study, Psychopharmacol Bull 27:31-39.
50. Robinson DS, Roberts DL, Smith JM, Stringfellow JC, Kaplita SB, Seminara JA, Marcus RN (1996) The safety profile of nefazodone. J Clin Psychiatry 57 (Suppl. 2):31-38.
51. Rouillon F, Phillips R, Serrurier D, Ansart E, Gerard MJ (1989) Rechutes de dépression unipolaire et efficacité de la maprotiline. L'Encéphale 15:527-534.
52. Rush AJ, Armitage R, Gillin JC, Yonkers KA, Winokur A, Moldofsky H, et al. (1998) Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 44:3-14.
53. Rush AJ, Trivedi MH (1995) Treating depression to remission. Psychiatry Ann 25:704-709.
54. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, Zajecka J (1997) Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. J Clin Psychiatry 58 (Suppl. 7):5-10.
55. Stein MK, Rickels K, Weise CC. Maintenance therapy with amitriptyline: a controlled trial (1980) Am J Psychiatry 137:370-371.
56. Szabadi E (1992) Fluvoxamine withdrawal syndrome. Br J Psychiatry 160:283-284.
57. Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, et al. (1995) Pharmacology and neurochemistry of nefazodone, a novel antidepressive drug. J Clin Psychiatry 56 (Suppl. 6):3-11.
58. Zajecka J, Tracy KA, Mitchell S (1997) Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58:291-297.